Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Acquisitions & Divestments (2022 - 2024)

Gain Therapeutics has reported Change in Acquisitions & Divestments over the past 3 years, most recently at -$42502.0 for Q4 2024.

  • Quarterly results put Change in Acquisitions & Divestments at -$42502.0 for Q4 2024, down 101.35% from a year ago — trailing twelve months through Dec 2024 was $5.0 million (down 59.0% YoY), and the annual figure for FY2024 was $5.0 million, down 59.0%.
  • Change in Acquisitions & Divestments for Q4 2024 was -$42502.0 at Gain Therapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for GANX hit a ceiling of $4.1 million in Q1 2023 and a floor of -$42502.0 in Q4 2024.
  • Median Change in Acquisitions & Divestments over the past 3 years was $2.5 million (2022), compared with a mean of $2.4 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: soared 51.45% in 2023 and later tumbled 101.35% in 2024.
  • Gain Therapeutics' Change in Acquisitions & Divestments stood at $2.1 million in 2022, then surged by 51.45% to $3.1 million in 2023, then tumbled by 101.35% to -$42502.0 in 2024.
  • The last three reported values for Change in Acquisitions & Divestments were -$42502.0 (Q4 2024), $2.0 million (Q2 2024), and $3.0 million (Q1 2024) per Business Quant data.